Thursday, March 5, 2015

Amphastar Pharmaceuticals - Barchart's Chart of the Day

Amphastar Pharmaceuticals (AMPH) is the Barchart Chart of the Day.  The generic drug company has a Trend Spotter buy signal, a Weighted Alpha of 51.30+ and gained 65.97% in the last month.

The Chart of the Day is Amphastar Pharmaceuticals (AMPH).  I found the stock by sorting the All Time High list for the stock with the highest technical buy signals then used the Flipchart feature to review the charts.  Since the Trend Spotter signaled a buy n 12/2 the stock gained 32.00%.

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use.


 Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barcart technical indicators:
  • 100% Barchart technical buy signals
  • Trend Spotter by signal
  • Above its 20, 50 and 100 day moving averages
  • 6 new highs and up 12.58% in the last month
  • Relative Strength Index 78.14%
  • Barchart computes a technical support level at 13.67
  • Recently traded at 14.52 with a 50 day moving average of 12.55
Fundamental factors:
  • Market Cap $648.17 million
  • Revenue expected to grow by 1.30% next year
  • Earnings estimated to compound at an annual rate of 5.00% for the next 5 years
  • Wall Street analysts issued 3 strong buy and 1 buy recommendation on the stock
The 50-100 Day MACD Oscillator has been an effective technical trading strategy on this stock and should continue to be used for entry and exit points.

No comments:

Post a Comment